, /PRNewswire/ -- Precision for Medicine, the archetypal biomarker-driven objective probe enactment (CRO) supporting beingness sciences companies successful the usage of biomarkers indispensable to targeting diligent treatments much precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) inaugural which improved the accuracy and velocity of identifying crab mutations successful coagulated tumors, allowing researchers and manufacturers to make patient-specific diagnostics for improved objective outcomes.
Collaborating with Thermo Fisher, Precision for Medicine performed a wide screening of samples from Precision's extended biorepository for cardinal mutations crossed 11 crab indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder and others. This signifier of the inaugural utilized Precision's expansive room of formalin-fixed, paraffin-embedded (FFPE) tumor tissues.
During the astir two-year project, tumors were screened connected Thermo Fisher's Ion Torrent Genexus System with the Thermo Fisher Oncomine Precision Assay GX, which includes the astir prevalent and perchance applicable crab operator variants crossed 50 genes. The assay is designed to observe 2,769 variants, including blistery spot mutations, transcript fig saltation (CNV) genes and fusion isoforms.
"This inaugural unveiled the genomic profiles of thousands of tumors successful our biospecimen library, making them almighty gathering blocks for exploring illness drivers, cause targets, diagnostic find and detecting caller mutations ne'er identified before," says Darren Davis, PhD, Senior Vice President astatine Precision for Medicine.
"Aided by precocious automation, much than 15,000 tumor samples were screened with occurrence rates exceeding 90% and with mutation prevalence identified successful much than 75% of tissues. This screening process proved to beryllium implicit 3 times faster than accepted methods. Accelerating the validation and regulatory support process volition yet pb to faster improvement of personalized (targeted) therapeutics and diagnostics for patients."
Davis adds, "Precision for Medicine plans to proceed to surface thousands of further subjects successful an open-ended observational registry crossed a scope of crab indications. This go-forward registry volition incorporated further NGS assay contented and caller liquid biopsy trial methods, to make an enriched biorepository and database derived from matched tissue-whole humor specimens. Ongoing enactment includes utilizing these tumors to enactment cross-site validation of caller diagnostics for regulatory approval."
Comprehensive results of this collaborative effort volition beryllium presented astatine the Association for Molecular Pathology's Annual Meeting and Expo successful Phoenix: Efficient biorepository improvement utilizing the Oncomine Precision Assay and the Ion Torrent™ Genexus™ integrated NGS platform; # I017 November 5 @ 9:15–10:15 a.m.
About Precision for Medicine
Precision for Medicine is the archetypal biomarker-driven objective probe services enactment supporting beingness sciences companies successful the usage of biomarkers indispensable to targeting diligent treatments much precisely and effectively. Precision applies caller biomarker approaches to objective probe that integrate objective proceedings execution with heavy technological knowledge, laboratory expertise, and precocious information sciences. This convergence of trials, labs, and information sciences is driving faster objective improvement and approval. Precision for Medicine is portion of Precision Medicine Group with implicit 3000 radical successful 40 locations successful the U.S., Canada, and Europe. For much information, visit https://www.precisionformedicine.com.
For Media Inquiries, Please Contact:
Ann Smith
Vice President, Coyne PR
Email: [email protected]
Phone: 201-680-9447
SOURCE Precision for Medicine
English (US)